Logo image of LMAT

LEMAITRE VASCULAR INC (LMAT) Stock Fundamental Analysis

NASDAQ:LMAT - Nasdaq - US5255582018 - Common Stock - Currency: USD

80.93  +0.16 (+0.2%)

Fundamental Rating

7

Overall LMAT gets a fundamental rating of 7 out of 10. We evaluated LMAT against 187 industry peers in the Health Care Equipment & Supplies industry. LMAT scores excellent points on both the profitability and health parts. This is a solid base for a good stock. LMAT has a decent growth rate and is not valued too expensively. These ratings would make LMAT suitable for quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

LMAT had positive earnings in the past year.
LMAT had a positive operating cash flow in the past year.
In the past 5 years LMAT has always been profitable.
LMAT had a positive operating cash flow in each of the past 5 years.
LMAT Yearly Net Income VS EBIT VS OCF VS FCFLMAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

1.2 Ratios

LMAT has a Return On Assets of 8.12%. This is amongst the best in the industry. LMAT outperforms 91.44% of its industry peers.
LMAT has a Return On Equity of 12.99%. This is amongst the best in the industry. LMAT outperforms 89.84% of its industry peers.
LMAT's Return On Invested Capital of 7.67% is amongst the best of the industry. LMAT outperforms 86.10% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for LMAT is in line with the industry average of 7.91%.
Industry RankSector Rank
ROA 8.12%
ROE 12.99%
ROIC 7.67%
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
LMAT Yearly ROA, ROE, ROICLMAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

LMAT's Profit Margin of 19.96% is amongst the best of the industry. LMAT outperforms 94.65% of its industry peers.
In the last couple of years the Profit Margin of LMAT has grown nicely.
Looking at the Operating Margin, with a value of 23.43%, LMAT belongs to the top of the industry, outperforming 94.12% of the companies in the same industry.
LMAT's Operating Margin has improved in the last couple of years.
LMAT has a Gross Margin of 68.80%. This is in the better half of the industry: LMAT outperforms 77.54% of its industry peers.
In the last couple of years the Gross Margin of LMAT has remained more or less at the same level.
Industry RankSector Rank
OM 23.43%
PM (TTM) 19.96%
GM 68.8%
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
LMAT Yearly Profit, Operating, Gross MarginsLMAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

7

2. Health

2.1 Basic Checks

LMAT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, LMAT has more shares outstanding
The number of shares outstanding for LMAT has been increased compared to 5 years ago.
The debt/assets ratio for LMAT is higher compared to a year ago.
LMAT Yearly Shares OutstandingLMAT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
LMAT Yearly Total Debt VS Total AssetsLMAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 7.18 indicates that LMAT is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 7.18, LMAT belongs to the best of the industry, outperforming 86.10% of the companies in the same industry.
LMAT has a debt to FCF ratio of 4.09. This is a neutral value as LMAT would need 4.09 years to pay back of all of its debts.
LMAT's Debt to FCF ratio of 4.09 is amongst the best of the industry. LMAT outperforms 85.56% of its industry peers.
LMAT has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
LMAT has a Debt to Equity ratio of 0.48. This is comparable to the rest of the industry: LMAT outperforms 42.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 4.09
Altman-Z 7.18
ROIC/WACC0.87
WACC8.81%
LMAT Yearly LT Debt VS Equity VS FCFLMAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.3 Liquidity

LMAT has a Current Ratio of 16.49. This indicates that LMAT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 16.49, LMAT belongs to the top of the industry, outperforming 97.86% of the companies in the same industry.
LMAT has a Quick Ratio of 13.83. This indicates that LMAT is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 13.83, LMAT belongs to the best of the industry, outperforming 95.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.49
Quick Ratio 13.83
LMAT Yearly Current Assets VS Current LiabilitesLMAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

6

3. Growth

3.1 Past

LMAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.13%, which is quite impressive.
Measured over the past years, LMAT shows a quite strong growth in Earnings Per Share. The EPS has been growing by 17.13% on average per year.
The Revenue has grown by 13.19% in the past year. This is quite good.
Measured over the past years, LMAT shows a quite strong growth in Revenue. The Revenue has been growing by 13.41% on average per year.
EPS 1Y (TTM)31.13%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%9.09%
Revenue 1Y (TTM)13.19%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%11.95%

3.2 Future

Based on estimates for the next years, LMAT will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.65% on average per year.
The Revenue is expected to grow by 9.07% on average over the next years. This is quite good.
EPS Next Y13.23%
EPS Next 2Y11.97%
EPS Next 3Y12.28%
EPS Next 5Y8.65%
Revenue Next Year11.52%
Revenue Next 2Y10.16%
Revenue Next 3Y10.14%
Revenue Next 5Y9.07%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
LMAT Yearly Revenue VS EstimatesLMAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
LMAT Yearly EPS VS EstimatesLMAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0.5 1 1.5 2 2.5

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 40.87, the valuation of LMAT can be described as expensive.
LMAT's Price/Earnings ratio is a bit cheaper when compared to the industry. LMAT is cheaper than 70.59% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.35. LMAT is valued slightly more expensive when compared to this.
With a Price/Forward Earnings ratio of 33.27, LMAT can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, LMAT is valued a bit cheaper than the industry average as 70.59% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 37.54. LMAT is around the same levels.
Industry RankSector Rank
PE 40.87
Fwd PE 33.27
LMAT Price Earnings VS Forward Price EarningsLMAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, LMAT is valued a bit cheaper than the industry average as 73.26% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, LMAT is valued a bit cheaper than the industry average as 76.47% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 44.46
EV/EBITDA 22.48
LMAT Per share dataLMAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of LMAT may justify a higher PE ratio.
A more expensive valuation may be justified as LMAT's earnings are expected to grow with 12.28% in the coming years.
PEG (NY)3.09
PEG (5Y)2.39
EPS Next 2Y11.97%
EPS Next 3Y12.28%

6

5. Dividend

5.1 Amount

LMAT has a yearly dividend return of 0.97%, which is pretty low.
Compared to an average industry Dividend Yield of 1.91, LMAT pays a better dividend. On top of this LMAT pays more dividend than 92.51% of the companies listed in the same industry.
With a Dividend Yield of 0.97, LMAT pays less dividend than the S&P500 average, which is at 2.36.
Industry RankSector Rank
Dividend Yield 0.97%

5.2 History

On average, the dividend of LMAT grows each year by 13.60%, which is quite nice.
LMAT has been paying a dividend for at least 10 years, so it has a reliable track record.
LMAT has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)13.6%
Div Incr Years13
Div Non Decr Years13
LMAT Yearly Dividends per shareLMAT Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

LMAT pays out 33.89% of its income as dividend. This is a sustainable payout ratio.
The dividend of LMAT is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP33.89%
EPS Next 2Y11.97%
EPS Next 3Y12.28%
LMAT Yearly Income VS Free CF VS DividendLMAT Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
LMAT Dividend Payout.LMAT Dividend Payout, showing the Payout Ratio.LMAT Dividend Payout.PayoutRetained Earnings

LEMAITRE VASCULAR INC

NASDAQ:LMAT (7/25/2025, 10:32:43 AM)

80.93

+0.16 (+0.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners94.92%
Inst Owner Change0.81%
Ins Owners8.54%
Ins Owner Change-3.07%
Market Cap1.83B
Analysts76.47
Price Target106.59 (31.71%)
Short Float %7.05%
Short Ratio8.22
Dividend
Industry RankSector Rank
Dividend Yield 0.97%
Yearly Dividend0.64
Dividend Growth(5Y)13.6%
DP33.89%
Div Incr Years13
Div Non Decr Years13
Ex-Date05-15 2025-05-15 (0.2)
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.01%
Min EPS beat(2)-5.52%
Max EPS beat(2)-2.5%
EPS beat(4)2
Avg EPS beat(4)2.64%
Min EPS beat(4)-5.52%
Max EPS beat(4)10.44%
EPS beat(8)6
Avg EPS beat(8)5.59%
EPS beat(12)7
Avg EPS beat(12)-0.64%
EPS beat(16)8
Avg EPS beat(16)-1.01%
Revenue beat(2)1
Avg Revenue beat(2)-0.28%
Min Revenue beat(2)-2.38%
Max Revenue beat(2)1.83%
Revenue beat(4)2
Avg Revenue beat(4)-0.13%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)1.83%
Revenue beat(8)4
Avg Revenue beat(8)-0.14%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)7
Avg Revenue beat(16)-0.34%
PT rev (1m)0%
PT rev (3m)-1.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.06%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.6%
Valuation
Industry RankSector Rank
PE 40.87
Fwd PE 33.27
P/S 8.08
P/FCF 44.46
P/OCF 38.01
P/B 5.26
P/tB 7.39
EV/EBITDA 22.48
EPS(TTM)1.98
EY2.45%
EPS(NY)2.43
Fwd EY3.01%
FCF(TTM)1.82
FCFY2.25%
OCF(TTM)2.13
OCFY2.63%
SpS10.02
BVpS15.39
TBVpS10.94
PEG (NY)3.09
PEG (5Y)2.39
Profitability
Industry RankSector Rank
ROA 8.12%
ROE 12.99%
ROCE 9.98%
ROIC 7.67%
ROICexc 17.81%
ROICexgc 31.73%
OM 23.43%
PM (TTM) 19.96%
GM 68.8%
FCFM 18.17%
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
ROICexc(3y)14.32%
ROICexc(5y)13.54%
ROICexgc(3y)28.83%
ROICexgc(5y)29.82%
ROCE(3y)10.75%
ROCE(5y)11.62%
ROICexcg growth 3Y-0.4%
ROICexcg growth 5Y7.52%
ROICexc growth 3Y9.22%
ROICexc growth 5Y8.43%
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
F-Score5
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 4.09
Debt/EBITDA 2.67
Cap/Depr 70.88%
Cap/Sales 3.08%
Interest Coverage 250
Cash Conversion 76.52%
Profit Quality 91.04%
Current Ratio 16.49
Quick Ratio 13.83
Altman-Z 7.18
F-Score5
WACC8.81%
ROIC/WACC0.87
Cap/Depr(3y)60.87%
Cap/Depr(5y)52.43%
Cap/Sales(3y)2.97%
Cap/Sales(5y)2.88%
Profit Quality(3y)96.62%
Profit Quality(5y)110.46%
High Growth Momentum
Growth
EPS 1Y (TTM)31.13%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%9.09%
EPS Next Y13.23%
EPS Next 2Y11.97%
EPS Next 3Y12.28%
EPS Next 5Y8.65%
Revenue 1Y (TTM)13.19%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%11.95%
Revenue Next Year11.52%
Revenue Next 2Y10.16%
Revenue Next 3Y10.14%
Revenue Next 5Y9.07%
EBIT growth 1Y29.64%
EBIT growth 3Y12.81%
EBIT growth 5Y19.77%
EBIT Next Year37.67%
EBIT Next 3Y21.1%
EBIT Next 5YN/A
FCF growth 1Y126.79%
FCF growth 3Y7.14%
FCF growth 5Y28.96%
OCF growth 1Y109.55%
OCF growth 3Y7.93%
OCF growth 5Y25.49%